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Olopatadine hydrochloride (olopatadine) is an antiallergic drug with histamine H1 receptor antagonistic activity. Recently,
olopatadine has been shown to bind to S100A12 which is a member of the S100 family of calcium-binding proteins, and exerts
multiple proinﬂammatory activities including chemotaxis for monocytes and neutrophils. In this study, we examined the possibil-
ity that the interaction of olopatadine with S100A12 inhibits the proinﬂammatory eﬀects of S100A12. Pretreatment of olopatadine
with S100A12 reduced migration of THP-1, a monocyte cell line, induced by S100A12 alone, but did not aﬀect recombinant hu-
man regulated upon activation, normal T cell expressed and secreted (RANTES)-induced migration. Amlexanox, which also binds
to S100A12, inhibited the THP-1 migration induced by S100A12. However, ketotifen, another histamine H1 receptor antagonist,
had little eﬀect on the activity of S100A12. These results suggest that olopatadine has a new mechanism of action, that is, suppres-
sion of the function of S100A12, in addition to histamine H1 receptor antagonistic activity.
Copyright © 2006 Kazuya Kishimoto et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
S100A12 belongs to the S100 family of EF-hand-type calci-
um-binding proteins [1]. These proteins are involved in the
regulation of a variety of intracellular activities, including
protein phosphorylation, enzymatic activities, Ca2+ home-
ostasis, and intermediate ﬁlament polymerization [2]. On
the other hand, several S100 proteins including S100A12
are secreted and have extracellular activities [2]. S100A12
belongs to a subset of the S100 protein family, which is
termed the myeloid-related proteins (MRPs) [3–5], because
expression of these proteins is almost completely restricted
to cells of myeloid origin, such as neutrophils and mono-
cytes. MRPs have proinﬂammatory eﬀects in the extracellu-
larmilieu[6,7].S100A12isdetectedinthesynovialﬂuidand
plasma of patients with gout, rheumatoid arthritis, and pso-
riatic arthritis [8], suggesting that S100A12 may be involved
in the inﬂammation in these diseases.
S100A12 from bovine lung extract was identiﬁed as a
ligand for the receptor for advanced glycation end prod-
ucts (RAGE), which is expressed on macrophages, endothe-
lium, and lymphocytes. Endothelial cells incubated with
S100A12 exhibited increased expression of intercellular ad-
hesion molecule-1 and vascular cell adhesion molecule-1
through the activation of nuclear factor-κ B[ 9]. In addition,
S100A12 induced the expression of tumor necrosis factor-
α and interleukin-1β in a murine macrophage cell line [8].
Footpad injection of bovine S100A12 into mice resulted in
the inﬁltration of leukocytes, and anti-S100A12 antibody
blocked leukocyte recruitment in murine models of delayed-
type hypersensitivity induced by methylated bovine serum
albumin [9]. Furthermore, human recombinant S100A12
has been reported to be chemotactic for neutrophils and
monocytes in vitro and in vivo [10, 11]. Thus, S100A12 and
RAGE are attractive targets for the treatment of inﬂamma-
tion.
Ithasbeenreported thatanti-allergicdrugs/mastcellsta-
bilizers such as amlexanox and cromolyn speciﬁcally bind
to S100A12 and S100A13 which are another member of the
S100 protein family [12]. It has also been reported that am-
lexanox repressed the ﬁbroblast growth factor 1 (FGF-1) re-
lease induced by S100A13 [13, 14]. Therefore, it is expected
that binding of these drugs to S100A12 result in the inhibi-
tion of its function, which may contribute to antiallergic or
anti-inﬂammatory eﬀects of these drugs.
Olopatadine hydrochloride (olopatadine: (Z)-11-(3-Di-
methylaminopropylidene)-6,11-dihydrodibenz [b,e]oxepin-
2-acetic acid monohydrochloride, ALLELOCK,K y o w a
Hakko Kogyo Co, Ltd, Japan) is an antiallergic agent with
histamine H1 receptor antagonistic action that is indicated2 Mediators of Inﬂammation
for the signs and symptoms of allergic rhinitis, chronic ur-
ticaria, eczema dermatitis, prurigo, pruritis cutaneous, pso-
riasis vulgaris, and erythema exsudativum multiform [15].
Olopatadine exhibits potent antihistamine activity in vivo
following its systemic administration. In addition to its po-
tent antihistaminic eﬀect, previous studies have demon-
strated that olopatadine inhibits the release of inﬂamma-
tory lipid mediators such as leukotrienes and thromboxanes
from human polymorphonuclear leukocytes and eosinophils
[15]. Olopatadine also reduces the tachykinin release from
peripheral sensory nerve endings [16]. Olopatadine inhibits
eosinophil inﬁltration in both rat allergic rhinitis and mice
chronic contact hypersensitivity models [17, 18]. However,
the precise mechanism of inhibitory eﬀects of olopatadine
on inﬁltration of leukocytes is still unclear.
Recently, Okada et al have found that olopatadine binds
speciﬁcallytoS100A12andS100A13inacalcium-dependent
manner as amlexanox and cromolyn do [19]. In the present
study, we examined the inhibitory eﬀect of olopatadine on
the function of recombinant human S100A12.
MATERIALS AND METHODS
Materials
Olopatadine hydrochloride (olopatadine) was synthesized in
Yokkaichi Plant, Kyowa Yuka Co, Ltd (Mie, Japan). Keto-
tifen fumarate (ketotifen) was purchased from Sigma Chem-
ical (St Louis, Mo, USA). Amlexanox was extracted from
SOLFA tabletspurchasedfromTakedaChemicalIndustries
Inc (Osaka, Japan). These drugs were dissolved in DMSO.
Recombinant human regulated upon activation, normal T
cell expressed and secreted (RANTES) was purchased from
R&D SYSTEMS (Minneapolis, Minn, USA).
RecombinantS100A12protein
Human S100A12 cDNA was a gift from Dr Ryoji Kobayashi
(Department of Signal Transduction Sciences, Kagawa Uni-
versity Faculty of Medicine, Kagawa, Japan). Recombinant
protein was expressed in E coli strain BL21 (DE3) and pu-
riﬁed as previously described by Yamashita et al [20], with
some modiﬁcations. Brieﬂy, 300mL DE3 culture was grown
at 37◦C to an OD600 of 0.6–0.8 and induced with 1mmol/L
isopropyl-β-D-thiogalactopyranoside for 4h at 37◦C. The
cell pellet was resuspended in hypotonic buﬀer, 10mmol/L
Tris-HCl (pH 7.5) containing 1mmol/L ethylenediaminete-
traacetic acid, and then centrifuged at 10000g for 60min.
The supernatant was dialyzed against 20mmol/L Tris-HCl
(pH 7.5) (buﬀer A), and loaded onto a HiPrep 16/10 Q XL
column (Amersham Biosciences, Piscataway, NJ, USA) equi-
librated with buﬀer A. The protein was eluted with a linear
gradient from 0 to 250mmol/L NaCl. Fractions containing
the protein were pooled and loaded onto a HiLoad 16/60
Superdex 75pg (Amersham Biosciences) equilibrated with
buﬀer A. Fractions containing the protein were pooled and
further puriﬁed using a Mono Q HR 5/5 column (Amer-
sham Biosciences) equilibrated with buﬀer A. The protein
was eluted with a linear gradient from 0 to 200mmol/L
NaCl, and stored at −80◦C. Purity was conﬁrmed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. In S100-
A12 preparations used for this study, endotoxin levels were
less than 0.1pg/μg of S100A12 as measured by the limulus
amebocyte assay (Bio Whittaker, Walkersville, Md, USA).
Cellculture
HumanmonocyticTHP-1cells(AmericanTypeCultureCol-
lection, Manassas, Va, USA) were cultured in RPMI 1640
supplemented with 10vol% heat-inactivated fetal bovine
serum (FBS) (Cansera, Etobicoke, ON, Canada), 100U/mL
penicillin and 100μg/mL streptomycin (Invitrogen, Grand
Island, NY, USA) at 37◦C5 %C O 2 in air.
Cellmigrationassay
The migration of THP-1 monocytes was studied using a
Chemotaxicell 24-well disposable chamber with 5μmp o r e s
(Kurabo Industries Ltd, Osaka, Japan). Cultured cells were
harvested and washed three times with Hank’s balanced salt
solution and then re-suspended in assay medium (RPMI
1640 with 0.5vol% heat-inactivated FBS, 10mmol/L N-
(2-hydroxyethyl)piperazine-N’-(4-butanesulfonic acid), pH
7.4). Each drug and stimulant were premixed in the assay
medium and incubated at 37◦Cf o r3 0 m i n .T h e n0 .05mL
of the mixture was placed into the lower chamber contained
0.45mL/well of the assay medium. Then 0.2mLofcellsus-
pension (6 × 105 cells) was added to the upper chamber
and incubated for 3h at 37◦Ci n5 %C O 2. Cells passing
through the membrane were collected from the lower well
andcountedwiththeEPICSXL/MCLﬂowcytometrysystem
(Beckman Coulter, Fullerton, Calif, USA) followed by mix-
ing of a predetermined number of ﬂow-count ﬂuorospheres
(Beckman Coulter). The total number of cells that had mi-
grated to the lower wells was determined by the ratio of cells
to ﬂuorospheres using the following formula: cells per mi-
croliter = [(cells counted)/(ﬂuorospheres counted)] × ﬂuo-
rospheres/microliter. Each sample was assayed in triplicate.
Statisticalanalysis
Data were presented as means ± SE. The Student t test fol-
lowing the F-test was used for analysis of diﬀerences between
two groups. Multiple comparisons among treatment groups
were assessed by one-way analysis of variance, followed by
the Dunnett’s test. Values of P<. 05 were considered statis-
tically signiﬁcant. All statistical calculations were performed
with the Statistical Analysis System (SAS Institute, Cary, NC,
USA).
RESULTS
EffectsofolopatadineonthemigrationofTHP-1
monocytesinducedbyS100A12orRANTES
The migration of THP-1 monocytes was studied in the
presence of S100A12 or RANTES. S100A12 induced theKazuya Kishimoto et al 3
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Figure 1: Eﬀects of olopatadine on the migration of THP-1 cells in-
ducedbyS100A12(a)orRANTES(b).Thenumbersofcellsmigrat-
ingtowardS100A12(1μmol/L)orRANTES(10nmol/L)during3h
incubation were determined by ﬂow cytometry. The values in panel
(a) are means ± SE from 3 independent experiments (n = 9), and
those in panel (b) are means ± SE from 2 independent experiments
(n = 6). ∗∗P<0.01; ∗∗∗P<0.001 (versus control, Dunnett’s test).
Media, spontaneous migration.
migration of THP-1 cells at concentrations between 0.75
and 2μmol/L (data not shown). Therefore, we examined
the eﬀect of olopatadine on the activity of S100A12 at
1μmol/L, a submaximal concentration. After pretreatment
of S100A12 for 30min, 26095 ± 1044 cells/well migrated
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Figure 2: Comparison of the abilities of olopatadine (open circle)
and amlexanox (closed circle) to inhibit THP-1 migration induced
by S100A12. Migration assay was performed as described for the
prior experiments. Values are percentages of control, and are the
means of 2 independent experiments.
to the bottom chamber at 1μmol/L of S100A12, indicat-
ing a 3.4-fold increase in comparison with the control value
of 7699 ± 693 cells/well (Figure 1(a)). On the other hand,
RANTES caused a 6.0-fold increase in the migration of THP-
1 cells at 10nmol/L (Figure 1(b)). As shown in Figure 1(a),
pretreatment of S100A12 with olopatadine resulted in a
concentration-dependent reduction of THP-1 cell migration
induced by S100A12, although the reduction was only par-
tial. The reduction of THP-1 cell migration by olopatadine
is apparently not caused by inhibition of cell motility, since
parallel studies showed that olopatadine had no eﬀect on the
migration of cells induced by RANTES (Figure 1(b)).
EffectofamlexanoxonTHP-1migration
inducedbyS100A12
Amlexanox is also reported to bind to S100A12 [12]. In ad-
dition, it has already been reported that amlexanox binds
to S100A13 and represses the FGF-1 release induced by
S100A13 [13, 14]. Accordingly, it is expected that amlex-
anox also inhibits the function of S100A12. Figure 2 shows
that amlexanox suppressed THP-1 migration induced by
S100A12 more eﬃciently than olopatadine. While amlex-
anox suppressed the THP-1 migration induced by RANTES
to some extent (data not shown), it was weak in this re-
spect compared with inhibition of migration by S100A12. It
is likely that amlexanox suppresses the eﬀect of S100A12 by
binding to S100A12 rather than by inhibiting cell motility.
EffectsofketotifenonthemigrationofTHP-1cells
inducedbyS100A12orRANTES
Next, to determine whether histamine H1 receptor antag-
onistic activity of olopatadine is related inhibition of the4 Mediators of Inﬂammation
00 .511 .522 .53
Migrated cells(×104 cells)
Ketotifen
Olopatadine
Control
Media
∗
(a)
00 .511 .522 .53
Migrated cells(×104 cells)
Ketotifen
Olopatadine
Control
Media
(b)
Figure 3: Eﬀects of olopatadine or ketotifen on the migration of
THP-1 cells induced by S100A12 (a) or RANTES (b). The num-
bers of cells migrating toward S100A12 (1μmol/L) or RANTES
(10nmol/L) during 3h incubation were counted. Values are means
± SE from 2 independent experiments (n = 6). ∗P<0.05 (versus
control, Student t test). Media, spontaneous migration.
activity of S100A12, ketotifen, another histamine H1 re-
ceptor antagonist, was tested. Figure 3 shows that ketotifen
(50μmol/L) did not aﬀect THP-1 migration induced by ei-
ther S100A12 and RANTES, though it has already been
shown that ketotifen has more potent histamine H1 recep-
tor antagonistic activity than olopatadine [21, 22]. These re-
sults suggest that olopatadine directly binds to S100A12 and
inhibits its function rather than histamine H1 receptor an-
tagonistic activity.
DISCUSSION
S100A12 has been identiﬁed as a binding protein to antial-
lergic drugs, such as olopatadine, amlexanox, and cromolyn,
using drug-aﬃnity columns [19]. S100A12 has multiple
inﬂammatory eﬀects [8–11]. If these drugs suppress the ac-
tivity of S100A12, a new anti-inﬂammatory mechanism of
action of these drugs can be demonstrated. In the present
study, we conﬁrmed that S100A12 induced the migration of
THP-1, a human monocytic cell line, at 1μmol/L, and then
that olopatadine and amlexanox suppressed this migration.
Moreover, these drugs had little eﬀect on the migration of
THP-1 cells induced by RANTES, suggesting that olopata-
dine and amlexanox bind to S100A12 speciﬁcally and sup-
press its activity.
Previous studies showed that S100A12 induced chemo-
tactic responses at much lower concentrations (0.01–
1nmol/L) [9, 10], whereas no response to S100A12 at lower
concentrations was detected in our experiments. Recently,
x-ray analysis has revealed two crystal forms of recombi-
nant S100A12 [21]. Therefore, the eﬀective concentration of
S100A12 may vary according to experimental conditions. It
is possible that in some conditions lesser amounts of drugs
are suﬃcient for suppression of the activity of. In fact, it is
necessary to examine the eﬀect of olopatadine on the func-
tion of S100A12 in vivo experiments.
Ketotifen in contrast to olopatadine did not suppress
the THP-1 migration induced by S100A12, suggesting that
olopatadine may have the distinctive feature of direct inhi-
bition of the function of S100A12. This new mechanism of
action of olopatadine may in addition to its potent histamine
H1 receptor antagonistic activity provide high degree of eﬃ-
cacy in the treatment of allergic diseases.
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